Bayer's Kidney Franchise Gains FDA Ground as a $7.25 Billion Legal Verdict Looms
Published on 09/19/2026 at 10:20 | Editorial boerse-global.de
Bayer shares slipped 2.3% on Friday to close at EUR 47.96, a retreat that market watchers struggled to pin on any single company-specific catalyst. The pullback came against a backdrop of genuine operational progress, suggesting investors remain hesitant to add exposure even as encouraging news flows out of the company's research labs.
A Regulatory Win in Kidney Care
The FDA has broadened the label for Kerendia, the company's finerenone-based therapy, to cover the treatment of chronic kidney disease in adults with type 1 diabetes, specifically for lowering albuminuria. For the Leverkusen-based group, the timing carries strategic weight as it works to reposition its pharmaceutical division around fresh growth drivers after several difficult years.
The approval rests on data from the Phase III FINE-ONE trial, which enrolled 242 patients over a six-month period. Kerendia cut the urine albumin-to-creatinine ratio by 34%, compared with 12% under placebo — a 25% stronger reduction of the marker than the dummy treatment. Safety monitoring remains part of the clinical picture: hyperkalemia occurred in 10.1% of participants versus 3.3% in the placebo arm, while therapy-related discontinuations stayed low at 1.7%.
Whether the drug becomes a commercial pillar hinges on how quickly physicians fold it into routine care for type 1 diabetics. Broad uptake will only materialize if the demonstrated benefit in reducing kidney damage outweighs the practical caution required in day-to-day practice.
Should investors sell immediately? Or is it worth buying Bayer?
Pipeline Momentum Beyond the Kidney Label
Bayer has also moved forward on other fronts. On September 9, a Phase II study began with BAY 3670549, a candidate being tested in patients with atrial fibrillation.
These clinical steps arrive as the company needs steady contributions from new indications. After the second quarter of 2026, group revenue reached EUR 10.87 billion, modestly above the prior-year figure of EUR 10.74 billion. Expanding the treated patient pool would reinforce long-term earnings power in the kidney business and help close gaps left by patent expirations on older products. A successful US rollout could also narrow the distance to the 52-week high of EUR 53.86.
Missouri Remains the Decisive Variable
Overshadowing the pipeline news is the unresolved legal legacy in the United States. A settlement totaling USD 7.25 billion has been struck to resolve claims alleging cancer risks, but a court ruling on final approval is still pending. For market participants, that judgment is the key to pricing the remaining financial exposure from the long-running US litigation with greater confidence.
Headwinds and Guardrails
The broader US healthcare environment presents its own challenges. Drug-pricing initiatives advanced through the Inflation Reduction Act are intensifying pressure on reimbursement rates for modern therapies. If payers restrict access to new products on their formularies, revenue growth could undershoot expectations. Clinical practice adds another hurdle: the need for regular potassium monitoring may make some physicians hesitant to start treatment early, and slow prescriptions in the type 1 segment would blunt the hoped-for share-price catalyst. In a weaker overall market, the stock would then be vulnerable to profit-taking.
Technically, the EUR 48.39 level — around the 50-day moving average — marks the line to watch. As long as it holds, the chart picture stays constructive and the market rewards pipeline progress. A sustained break below it, however, could open a consolidation phase in which broader skepticism toward the agriculture and pharma sectors regains the upper hand.
Bayer at a turning point? This analysis reveals what investors need to know now.
The next reliable gauge of the operating trend is already scheduled: on November 3, 2026, the company publishes its interim report for the third quarter. That release will show how much of the pharma division's momentum shows up in the numbers and whether full-year earnings targets remain on track. Until then, observers are likely to focus on early signals of Kerendia's prescription trajectory in the US.
Despite Friday's decline, the medium-term picture still reflects a recovery: Bayer shares are up 30% since the start of the year. Whether that uptrend holds will depend heavily on how quickly the company clears its legal uncertainties and translates operational progress into actual earnings.
Ad
Bayer Stock: New Analysis - 19 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
